EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Algal Antioxidant Carotenoid Diatoxanthin as a Modulator of Inflammation and Angiogenesis in Triple-Negative Breast Cancer Cells

Danilo Morelli, Luana Calabrone iD, Luisa Di Paola iD, Giovanna Chiorino iD, Paola Ostano iD, Douglas M Noonan iD, Giovanni Corso iD, Adriana Albini iD

Antioxidants · 04.02.2026 · 15 (2) · 205

DOI: 10.3390/antiox15020205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antioxidants, online erschienen am 04.02.2026. Verfasst von Danilo Morelli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Istituto Tumori di Milano, 20133 Milan, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Drugs and Vaccines from the Sea (ADViSE), "Fattoria La Vialla di Gianni, Antonio e Bandino Lo Franco-SAS" (Castiglion Fibocchi, Arezzo, Italy), IEO-MONZINO Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Algal carotenoids play a promising role in handling chronic diseases due to their diverse bioactive properties, including anti-inflammatory, antioxidant, and anticancer effects. This study assesses the activity of the antioxidant xanthophyll diatoxanthin (Dt), derived from marine diatoms, against triple-negative breast cancer (TNBC) cells using in vitro models, gene expression evaluation, and explores its role in potentiating the cytotoxic effect of chemotherapy. Dt exhibited selective activity against MDA-MB-231 and BT-549 TNBC cells at concentrations ≥12.5 ng/mL, with maximal effects observed at 25 ng/mL while sparing human umbilical vein endothelial cells (HUVECs) at these doses. When combined with doxorubicin (0.1–0.5 μM), Dt enhanced the anti-tumor efficacy in both TNBC cell lines, further reducing cell viability compared with doxorubicin alone (p < 0.05–0.001). Dt also exerted its activity in inhibiting migration and chemotaxis by approximately 30–50% compared with the controls (p < 0.01) and suppressing 3D-tumor spheroid growth at day 12 (up to >50% reduction, p < 0.001). Notably, secretome analysis revealed Dt-induced changes in inflammatory, oxidative and angiogenic mediators, highlighting its ability to modulate the TNBC microenvironment. Dt also downregulated key pro-survival, pro-angiogenic and pro-tumorigenic genes in both TNBC cell lines, supporting its role in disrupting oncogenic pathways. Angiogenesis-related genes were significantly reduced. Dt also decreased the expression of angiogenic mediators in HUVECs, supporting Dt’s role in inhibiting tumor vascularization. Results on gene expression regulation were also confirmed by RNA-Seq analysis. These findings pose Dt as a promising chemopreventing candidate in the challenging fight against TNBC, a well-known type of cancer that is aggressive and resistant to conventional therapies, targeting critical pathways for tumor survival, such as inflammation, angiogenesis, tumor cell growth, and cell migration. Given its selective activity against TNBC cells, ability to enhance chemotherapy efficacy, and modulation of the tumor microenvironment, Dt holds promise as a complementary drug for cancer prevention and interception. Future studies should focus on validating these effects in vivo and exploring Dt’s potential in combinatorial treatment strategies for cancer.

Schlagwörter

Stichwörter der Autor:innen

RNA-Seqangiogenesisantioxidantschemotherapydiatomsdiatoxanthinferroptosisinflammationtriple-negative breast cancer

Autor:innen und Institutionen

  • Fondazione IRCCS Istituto Tumori di Milano, 20133 Milan, Italy.
  • ISB-Ion Source & Biotechnologies Srl, 20017 Rho, Italy.
  • Unit of Chemical-Physics Fundamentals in Chemical Engineering, Department of Science and Technology, Università Campus Bio-Medico, 00128 Rome, Italy.
  • Lab of Cancer Genomics, Fondazione Edo ed Elvo Tempia, 13900 Biella, Italy.
  • Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.
  • Unit of Molecular Pathology, Biochemistry and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), MultiMedica, 20138 Milan, Italy.

ORCID-Profile: Luana Calabrone, Luisa Di Paola, Giovanna Chiorino, Paola Ostano, Douglas M Noonan, Giovanni Corso, Adriana Albini

Förderung

  • Drugs and Vaccines from the Sea (ADViSE)
  • "Fattoria La Vialla di Gianni, Antonio e Bandino Lo Franco-SAS" (Castiglion Fibocchi, Arezzo, Italy)
  • IEO-MONZINO Foundation
  • IRCCS IEO
  • Italian Ministry of Health Ricerca Corrente-IRCCS IEO
  • IRCCS MultiMedica
  • “Fattoria La Vialla di Gianni, Antonio e Bandino Lo Franco—SAS”
  • Italian Ministry of Health Ricerca Corrente–IRCCS IEO

Zitieren

APA

Morelli, D., Calabrone, L., Di Paola, L., Chiorino, G., Ostano, P., Noonan, D. M., Corso, G., & Albini, A. (2026). The Algal Antioxidant Carotenoid Diatoxanthin as a Modulator of Inflammation and Angiogenesis in Triple-Negative Breast Cancer Cells. Antioxidants, 15(2), 205. https://doi.org/10.3390/antiox15020205

Vancouver

Morelli D, Calabrone L, Di Paola L, Chiorino G, Ostano P, Noonan DM, et al. The Algal Antioxidant Carotenoid Diatoxanthin as a Modulator of Inflammation and Angiogenesis in Triple-Negative Breast Cancer Cells. Antioxidants. 2026;15(2):205. doi:10.3390/antiox15020205

BibTeX
@article{Morelli2026,
  author = {Morelli, Danilo and Calabrone, Luana and Di Paola, Luisa and Chiorino, Giovanna and Ostano, Paola and Noonan, Douglas M and Corso, Giovanni and Albini, Adriana},
  title = {The Algal Antioxidant Carotenoid Diatoxanthin as a Modulator of Inflammation and Angiogenesis in Triple-Negative Breast Cancer Cells},
  journal = {Antioxidants},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {205},
  doi = {10.3390/antiox15020205}
}
Kostenlos starten →